Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hürthle cell carcinoma.

E Yutan1, O H Clark

  • 1Mt. Zion/University of California, San Francisco Medical Center, Department of Surgery, 1600 Divisadero St., Room C-342, San Francisco, CA 94143-1674, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

Hürthle cell carcinoma (HCC) is an aggressive thyroid cancer. Treatment involves surgery, radioiodine ablation, and thyroid hormone therapy, with surgery also used for recurrent disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Invasion of metastatic human follicular thyroid cancer is inhibited via antagonism of protein kinase C.

Cancer letters·2008
Same author

Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma.

Surgery·2007
Same author

Laparoscopic bilateral adrenalectomy: results for 30 consecutive cases.

Surgical endoscopy·2007
Same author

Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary?

World journal of surgery·2006
Same author

Parathyroid surgery: we still need traditional and selective approaches.

Journal of endocrinological investigation·2005
Same author

Well differentiated thyroid cancer.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2005

Area of Science:

  • Endocrinology
  • Oncology
  • Surgical Oncology

Background:

  • Hürthle cell carcinoma (HCC) presents aggressive tumor characteristics.
  • Patients with HCC generally experience a poorer prognosis compared to papillary or follicular thyroid carcinomas.

Purpose of the Study:

  • To outline the recommended management and treatment strategies for Hürthle cell carcinoma.
  • To discuss the prognosis and surveillance of HCC patients.

Main Methods:

  • Surgical management including total thyroidectomy and neck dissection when indicated.
  • Post-operative radioiodine scanning for completeness assessment and remnant ablation.
  • Thyroid hormone replacement therapy for all patients.
  • Surgical intervention for recurrent disease or metastasis.

Main Results:

  • Fewer than 10% of Hürthle cell carcinomas demonstrate radioiodine uptake.
  • Surgical treatment for recurrent disease offers good palliation and survival extension.
  • Pulmonary wedge resection is effective for lung metastases.

Conclusions:

  • Comprehensive surgical treatment followed by radioiodine ablation is crucial for HCC management.
  • Thyroid hormone administration is essential due to thyrotropin receptor presence in most HCCs.
  • Recurrent HCC can be effectively managed with surgical interventions, prolonging life and improving palliation.

Related Experiment Videos